Form 4: Indaptus Director Natan Acquires Stock Options

Indaptus Therapeutics Director David Natan was granted options to purchase 25,000 shares of common stock as part of the company's non-employee director compensation program.

Summary

• David Natan, a Director of Indaptus Therapeutics, Inc. (INDP), acquired options to purchase 25,000 shares of common stock.
• The transaction date for the option grant was January 7, 2026.
• The exercise price for these options is $2.69 per share.
• The options were granted under the Issuer's non-employee director compensation program.
• These stock options will vest over three years, commencing from the grant date, in equal quarterly installments.
• Vesting is contingent upon David Natan's continued service on the Issuer's board of directors through each vesting date.
• The expiration date for these options is January 7, 2036.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation event for a director, which is generally a neutral to slightly positive signal as it aligns management incentives with shareholder interests, but does not indicate significant operational or financial news.

Positives

• The grant of stock options aligns the interests of Director David Natan with those of shareholders, incentivizing long-term company performance.
• This is a standard practice for non-employee director compensation, indicating a structured governance approach.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the granted options, which is contingent on continued service.

Management Comments

• The Reporting Person acquired options to purchase 25,000 shares of common stock pursuant to the Issuer's non-employee director compensation program.
• The stock options vest over three years commencing from the date of grant in equal quarterly installments subject to continued service on the Issuer's board of directors through each vesting date.

Industry Context

This transaction is a routine insider compensation event and does not provide specific insights into broader industry trends. It reflects standard practices for incentivizing non-employee directors in the biotechnology or pharmaceutical sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive for corporate governance, as it aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders.

Next Steps

• David Natan's continued service on the board of directors is required for the options to vest in equal quarterly installments over the next three years.

Key Dates

Keywords

Indaptus Therapeutics, INDP, stock options, director compensation, Form 4, insider transaction, equity incentive